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Abstract: Type 2 diabetes mellitus (DM2) is characterized by excessive hepatic gluconeo-
genesis, increased insulin resistance and a progressive inability of pancreatic beta cells to 
produce sufﬁ  cient insulin. DM2 evolves as a progression from normal glucose tolerance, to 
impaired glucose tolerance (IGT) to frank diabetes mellitus, reﬂ  ecting the establishment of 
insulin resistance and beta cell dysfunction. Insulin resistance not only contributes to impaired 
glycemic control in DM2, but to the development of hypertension, dyslipidemia and endothelial 
dysfunction. Cardiovascular disease is the primary morbidity for patients with DM2. The onset 
of insulin resistance and cardiovascular insult likely occurs well before the onset of IGT is 
detected clinically. Biguanides and thiazolidinediones (TZDs) are two classes of oral agents for 
the management of DM2 that improve insulin resistance, and thus have potential cardiovascular 
beneﬁ  ts beyond glycemic control alone. Metformin additionally inhibits hepatic gluconeogenesis. 
The combined use of two of these agents targets key pathophysiologic defects in DM2. Single 
pill combinations of rosiglitazone/metformin and pioglitazone/metformin have recently been 
approved for use in the US and Europe. This article reviews the clinical data behind the use of 
metformin in combination with TZDs for the management of diabetes, its impact on vascular 
health, side effects and potential mechanisms of action for combined use.
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Rationale for the combined 
use of thiazolidinediones and metformin 
from a cardiovascular perspective
Type 2 diabetes mellitus (DM2) is characterized by defects both in insulin secretion 
and insulin action (Ginsberg et al 1975; DeFronzo et al 1985; Lillioja et al 1988). With 
the use of the euglycemic insulin clamp technique, over the past two decades, it has 
become clear that DM2 evolves as a progression from normal glucose tolerance, to 
impaired glucose tolerance (IGT) to frank diabetes mellitus, reﬂ  ecting the establishment 
of insulin resistance and beta cell dysfunction (Ginsberg et al 1975; DeFronzo et al 
1985; Lillioja et al 1988; and reviewed in Granner and O’Brien (1992) and DeFronzo 
(2004)). This progression has been demonstrated in many populations, and is strongly 
correlated with the progression of obesity (Lillioja et al 1988). The progression from 
normal glucose homeostasis to IGT is associated with an increase in fasting plasma 
insulin and glucose-stimulated insulin secretion (post-prandial), and a decrease in 
sensitivity to insulin action (Saad et al 1988, 1989). The progression from IGT to frank 
DM2 is associated with an inability of the pancreatic beta cells to continue this excess 
secretion of insulin (Polonsky et al 1996; Roe et al 1996), however signiﬁ  cant beta 
cell dysfunction may occur much earlier (DeFronzo 2004). There is only a minimal Vascular Health and Risk Management 2007:3(4) 504
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additional worsening of insulin resistance at this stage of 
progression (DeFronzo 2004).
Cardiovascular disease is the primary morbidity for 
patients with DM2 (Howard et al 2002). The onset of insulin 
resistance itself seems to be an early event in the progression 
of DM2, precedes the development of overt hyperglycemia, 
and may contribute substantially to the development of 
cardiovascular disease independent of the hyperglycemia 
associated with DM2 (Meigs et al 2000; DeFronzo 2004). In 
the Framingham offspring study, elevated levels of fasting 
insulin were associated with impaired fibrinolysis and 
hypercoagulability, despite normal glucose tolerance (Meigs 
et al 2000). In the same study population, those with impaired 
fasting glucose had a 2.8 fold relative risk of cardiovascular 
events over a 4-year follow up period (Meigs et al 2002). 
Vascular dysfunction has been identiﬁ  ed in several groups 
of patients with normal blood glucose levels but insulin 
resistance including; ﬁ  rst degree relatives of patients with 
DM2 (Balletshofer et al 2000), patients with previous history 
of gestational diabetes (Bergholm et al 2003), patients with 
metabolic syndrome and patients with polycystic ovarian 
syndrome (reviewed in Caballero 2005). In the San Antonio 
heart study, impaired glucose tolerance was associated with 
hypertension, dyslipidemia, obesity and metabolic syndrome 
(Haffner et al 1990). Importantly, the risk of myocardial 
infarction (MI) in patients with known DM2, but without 
overt cardiovascular disease, is equal to patients who have 
had a previous MI but are free of diabetes (Haffner et al 
1998). This observation has lead many to recommend the 
treatment of individuals with diabetes as comparable to an 
individual with known coronary heart disease. Still, insulin 
resistance itself appears to be an important risk factor for car-
diovascular disease, even before the onset of hyperglycemia 
or DM2 (Wilson et al 2002, 2005).
Thiazolidinediones (TZDs) comprise a class of oral 
agents for the management of DM2 that, in addition to 
improvements in glycemic control, improve insulin resis-
tance and thus have potential cardiovascular beneﬁ  ts beyond 
glycemic control alone. TZDs emerged for clinical use in 
the late 1990s. TZDs are ligands for the transcription fac-
tor peroxisome proliferator-activated receptor-γ (PPARγ), 
a member of the nuclear receptor superfamily. PPARγ is 
expressed predominantly in adipose tissue, but also in macro-
phages, beta cells of the pancreas, endothelial cells and other 
tissues (Kato et al 1999; Kersten et al 2000). The Olefsky 
group noted increased insulin sensitivity and lower blood 
pressure in obese patients without diabetes who were treated 
with troglitazone (Nolan et al 1994). There is some evidence 
in animal models and in human studies that TZD treatment 
may preserve beta cell function, one of the important changes 
in the progression from IGT to DM2. Ovalle and colleagues 
studied a small group of DM2 patients poorly controlled on 
metformin and sulfonylurea and added either rosiglitazone 
or insulin. Both groups achieved similar glycemic control, 
but only the rosiglitazone group had improved beta cell 
function as indicated by several clinical measures (Ovalle 
and Bell 2004).
Most additional studies have noted lower fasting and 
postprandial blood glucose, free fatty acids and fasting 
insulin levels, suggesting that TZDs improve insulin sen-
sitivity (reviewed in Yki-Jarvinen 2004). For women with 
gestational diabetes, a state which reﬂ  ects IGT, TZD treat-
ment prevented the progression to DM2 (TRIPOD/PIPOD) 
(Xiang et al 2006). Pioglitazone has been shown to be 
effective in secondary prevention of macrovascular events 
in patients with known macrovascular disease. Over a 34 
month placebo-controlled RCT, Pioglitazone reduced risk 
in the secondary composite endpoint of all cause mortal-
ity, non fatal MI and stroke. A1C, triglycerides, LDL were 
all decreased and HDL was increased signiﬁ  cantly. There 
was an increase in congestive heart failure on pioglitazone 
(Dormandy et al 2005). A meta-analysis of 23 RCTs revealed 
a similar decrease in A1C (1–1.5%), but with an increase in 
weight (approximately 3 kg). Pioglitazone decreased TG, 
increased HDL and had no effect on LDL or total cholesterol. 
Rosiglitazone increased HDL, but was neutral on triglycer-
ides and increased TC and LDL (Chiquette et al 2004). A 
similar result on lipids is reported comparing addition of 
pioglitazone or rosiglitazone to patients on glimeperide which 
found pioglitazone addition lowered TC, LDL, TG and raised 
HDL, where rosiglitazone addition increased TC, LDL and 
TG, with no change on HDL (Derosa et al 2005a). This dif-
ference may be due to activation of PPARα by pioglitazone 
in addition to PPARγ, by contrast to rosiglitazone which more 
selectively activates PPARγ (Kersten et al 2000).
In addition to insulin resistance and beta cell failure, the 
other principle pathophysiologic defect in DM2 is excessive 
hepatic gluconeogenesis (Magnusson et al 1992). Metformin 
is a member of the biguanide class of antidiabetic agents. Its 
principle clinical efﬁ  cacy lies in its action to block hepatic 
gluconeogensis, and increase hepatic insulin sensitivity, and 
to a lesser extent increase insulin-mediated glucose uptake in 
fat and muscle tissue (Rossetti et al 1990; Perriello et al 1994; 
Bailey and Turner 1996; Large and Beylot 1999; Hundal et 
al 2000). Biguanide-containing compounds have been used 
since ancient times for the treatment of diabetes. Metformin Vascular Health and Risk Management 2007:3(4) 505
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has been used clinically for over 40 years, though it has only 
been approved in the United States since 1995. Follow up 
of patients enrolled in United Kingdom prospective diabetes 
study (UKPDS 34) suggest that the complications of diabetes 
can be related to those caused by hyperglycemia and those 
related to insulin resistance. In this study, a subgroup of obese 
patients treated with metformin had signiﬁ  cantly lower risk of 
any diabetes-related endpoint, all cause mortality, and stroke 
when compared to patients achieving similar glycemic con-
trol with a sulfonylurea or insulin therapy (UKPDS 1998).
Treatment or prevention of insulin resistance can prevent 
the progression from impaired glucose tolerance to overt 
diabetes. The diabetes prevention trial demonstrated that an 
intensive diet and exercise program for patients with IGT 
reduced the risk of progression to diabetes by 58%, and 
metformin treatment reduced progression to DM2 by 31% 
(Knowler et al 2002). Similarly, troglitazone or pioglitazone 
treatment of women with a history of gestational diabetes 
helped to prevent progression to overt DM2 and to preserve 
beta cell function (Xiang et al 2006). In the DREAM study, 
patients with impaired fasting glucose or impaired glucose 
tolerance, or both were randomized to receive rosiglitazone 
8 mg daily or placebo and followed for three years. The 
composite outcome was a combination of development 
of diabetes or death. 26% of patients in the placebo group 
developed the primary outcome versus only 11% in the rosi-
glitazone group (Gerstein et al 2006). Since insulin resistance 
itself contributes to risk of cardiovascular disease, treatment 
of insulin resistance is a potential pathophyisiologic target 
for the prevention of CVD, not just diabetes. Combined use 
of metformin and TZDs has theoretical beneﬁ  t as it targets 
two main pathophysiologic defects in DM2, increased 
gluconeogenesis and insulin resistance.
Clinical trials of combination use 
metformin/thiazolidinediones
Effects on glycemic control
As of May 2006, at least twelve clinical trials have been 
published in peer-reviewed journals designed to evaluate 
addition of TZD to metformin for the treatment of diabetes 
(Inzucchi et al 1998; Einhorn et al 2000; Fonseca et al 2000; 
Gomez-Perez et al 2002; Dailey et al 2004; Charbonnel 
et al 2005; Matthews et al 2005; Derosa et al 2005b; Weiss-
man et al 2005; Kendall et al 2006; Rosenstock et al 2006; 
Umpierrez et al 2006). The initial study that demonstrated 
efﬁ  cacy and metabolic effects of the combined use of met-
formin and TZDs was performed by the Shulman group at 
Yale (Inzucchi et al 1998). This study of 29 patients random-
ized to receive either metformin or troglitazone for three 
months, after which they were placed on both agents. Post-
prandial glucose was measured by mixed meal test. Insulin 
sensitivity was assessed with hyperinsulinemic-eugylcemic 
clamp at baseline, after three months of monotherapy and 
after three months of combination therapy. After three 
months of monotherapy, both metformin and troglitazone 
had similar decreases in fasting and postprandial plasma 
glucose levels. Metformin decreased endogenous glucose 
production, while troglitazone did not, consistent with the 
known effects of metformin on hepatic gluconeogeneis. 
Metformin had a 13% increase in insulin-mediated glucose 
disposal, while troglitazone had a 54% increase. Thus as 
single agents, metformin and troglitazone achieved similar 
glycemic control, metformin primarily through decreasing 
hepatic glucose production and troglitazone by improving 
insulin sensitivity. During combination therapy FPG was 
decreased an additional 41 mg/dl (18%), and postprandial 
glucose was decreased and additional 54 mg/dl (21%), both 
signiﬁ  cant changes from monotherapy. Adding troglitazone 
to metformin did not further decrease endogenous glu-
cose production, however signiﬁ  cantly increased glucose 
disposal. The addition of metformin to the troglitazone 
group produced only a modest increase in glucose disposal 
(Inzucchi et al 1998). Thus the main efﬁ  cacy of combined 
therapy seemed to be the effect of metformin to decrease 
endogenous glucose production and that of troglitazone to 
improve insulin sensitivity, together targeting two patho-
physiologic defects in DM2.
Troglitazone was taken off the market in 1999 because 
of concerns for hepatic toxicity. Subsequent studies of 
TZDs were with either rosiglitazone or pioglitazone. 
The ﬁ  rst randomized controlled trial of the combined use 
of metformin with TZD in a large population was with 
rosiglitazone, published in 2000. In this study, 348 dia-
betic patients were randomized to metformin plus placebo, 
metformin plus 4 mg/d rosiglitazone or metformin plus 
8 mg/d rosiglitazone for 26 weeks. The primary endpoint 
was glycemic control. In this interval, addition of 4 mg 
rosiglitazone to metformin lowered FPG by 33 mg/dl, A1C 
by 0.56. The 8 mg dose of rosiglitazone, lowered FPG 
by 48 mg/dl and A1C by 0.78, all statistically signiﬁ  cant 
changes. Treatment effects were seen by as early as 4 weeks 
of treatment. Insulin sensitivity was assessed by the homeo-
stasis model of assessment (HOMA), and both groups had 
increased sensitivity compared to the metformin-placebo 
group (Fonseca et al 2000).Vascular Health and Risk Management 2007:3(4) 506
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A RCT with pioglitazone randomized 328 patients 
to pioglitazone-metformin or metformin-placebo for 16 
weeks and found the pioglitazone group had a signiﬁ  cant 
A1c decrease of 0.83% compared to placebo-metformin. 
There was a signiﬁ  cant improvement in insulin resistance 
by HOMA-IR (Einhorn et al 2000). When a sulfonylurea 
is used with metformin as a control group rather than 
placebo-metformin, several studies have demonstrated 
similar glycemic control (Charbonnel et al 2005; Matthews 
et al 2005; Umpierrez et al 2006). Two studies by the same 
group compared more long term combination use of piogli-
tazone added to metformin (Charbonnel et al 2005; Matthews 
et al 2005). One was a one year double blind study that com-
pared metformin-pioglitazone combination with metformin-
gliclazide. The authors found similar decreases in A1C and 
FPG with each treatment (Matthews et al 2005). The study 
that went for two years also found similar reductions in A1C, 
and slightly better FPG with metformin-pioglitazone com-
bination compared with metformin-gliclazide (Charbonnel 
et al 2005). These results suggest that the glycemic effects 
of combination therapy with metformin-pioglitazone can be 
sustained for at least two years.
Of note, similar improvements in glycemic control with 
the combined use of metformin and thiazolidinediones were 
noted in Mexicans, who have a signiﬁ  cant burden of diabetes 
(Gomez-Perez et al 2002). Weissman and colleagues in a 
multi-center double blind RCT with 766 subjects compared 
adding rosiglitazone to 1000 mg of metformin with dose 
escalation of metformin for 24 weeks. They found improve-
ments in FPG and A1C with rosiglitazone-metformin over 
metformin dose escalation (Weissman et al 2005), a potential 
beneﬁ  t for patients unable to tolerate full dose metformin. 
In an open labeled RCT, Dailey and colleagues added rosi-
glitazone vs. placebo to patients already on metformin and 
glyburide. They found improved A1C and FPG with the 
addition of rosiglitazone (Dailey et al 2004). In a randomized, 
open-label parallel trial either insulin glargine or rosi-
glitazone was added to patients with inadequate glycemic 
control on metformin plus sulfonylurea. These authors found 
similar improvements in glycemic control with both regimens 
(Rosenstock et al 2006).
Cardiovascular effects of combined use 
of metformin-TZDs
The RCT by Fonseca and colleagues with rosiglitazone 
described above also looked at secondary endpoints known 
to be important for cardiovascular health with metformin-
rosiglitazone (Fonseca et al 2000). There were small but 
statistically signiﬁ  cant increases in HDL cholesterol. There 
were no changes in triglycerides. Total cholesterol and LDL 
levels were statistically increased with either rosiglitazone 
group (LDL levels increased from 112 mg/dl to 133 mg/dl 
in the 8 mg/d rosiglitazone-metformin group). Free fatty 
acid levels, which are a potential mediator of insulin resis-
tance, were decreased in both rosiglitazone groups. Both 
rosiglitazone groups had a small but signiﬁ  cant decrease in 
hemoglobin levels, weight gain (Fonseca et al 2000). Several 
other RCTs found worsening lipid proﬁ  les with the addition 
of rosiglitazone to metformin (Gomez-Perez et al 2002; 
Weissman et al 2005; Rosenstock et al 2006). The weight 
gain and increase in LDL are important considerations in 
patients already at risk for cardiovascular disease.
Two RCTs published with pioglitazone revealed statisti-
cally signiﬁ  cant improvements in TGs and HDL, but little 
change in TC or LDL (Einhorn et al 2000; Betteridge and 
Verges 2005), whereas two others from the same group 
found that at one year of combined therapy with metformin-
pioglitazone, TC, HDL and TG were improved, but LDL 
was elevated (Matthews et al 2005), but at two years pio-
glitazone-metformin group had improved TG, HDL and no 
change in LDL (Charbonnel et al 2005). These studies are 
somewhat consistent with the more beneﬁ  cial lipid proﬁ  le 
of pioglitazone compared to rosiglitazone as single agents 
(Chiquette et al 2004). Additionally, pioglitazone inﬂ  uences 
LDL particle size with an increase in large LDL particles and 
a decrease in small particles, consistent with a potentially less 
atherogenic cholesterol proﬁ  le (Perez et al 2004).
Insulin resistance is a central feature of the metabolic 
syndrome. An Italian study evaluated addition of glimepiride 
or rosiglitazone to metformin therapy for patients with poorly 
controlled DM2, hypertension, obesity and dyslipidemia. 
They found that addition of rosiglitazone to metformin 
brought about more rapid improvements in A1C and FPG, 
but glycemic control was similar at 12 months compared to 
addition of glimepiride to metformin. They did ﬁ  nd mod-
est but statistically signiﬁ  cant improvements in systolic 
blood pressure and diastolic blood pressure in patients on 
metformin-rosiglitazone compared to the metformin-
glimepiride group (Derosa et al 2005b).
Side effects and contraindications
Weight gain, edema and, depending on which TZD is 
selected, worsened lipid proﬁ  les are the most common side 
effects of adding a TZD to metformin and are similar to 
the side effects of the TZDs as single agents. The average 
weight gain on TZDs is 2.7 kg, with a range of 0.7 kg in a Vascular Health and Risk Management 2007:3(4) 507
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Japanese study to more than 3kd in non-Japansese studies 
(Chiquette et al 2004). In the largest study of TZD combined 
with metformin, weight gain of about 2 kg occurred on the 
highest rosiglitazone dose with metformin (Fonseca et al 
2000). Frank edema was present in about 4% of patients 
(GlaxoSmithKline 2007; Takeda Pharmaceuticals 2007), and 
body water retention is felt to contribute to about 75% of the 
weight gain on TZDs (Basu et al 2006). Insulin is a potent 
anti-natriuretic hormone (DeFronzo et al 1976), it may be 
that TZD treatment sensitizes to the anti-natriuretic actions 
of insulin, contributing to edema. Anemia was present in 
4% – likely the result of hemodilution associated with ﬂ  uid 
retention. Interestingly, a smaller part of weight gain comes 
from a re-distribution of fat from the visceral compartment 
to subcutaneous compartment (Miyazaki et al 2002). This 
visceral fat is classically considered more pathogenic in 
diabetes than subcutaneous fat, thus fat re-distribution is 
likely one of the major mechanisms by which TZDs mediate 
their beneﬁ  cial effects on insulin sensitivity (Gastaldelli et al 
2002). According to manufactures’ prescribing information, 
TZD/metformin is contraindicated in patient that exhibit 
clinical evidence of active liver disease or increased serum 
transaminase levels, renal disease or renal dysfunction (eg, 
as suggested by serum creatinine levels 1.5 mg/dL (males), 
1.4 mg/dL (females), acute or chronic metabolic acidosis. 
Although TZDs are contraindicated in acute liver disease, 
their insulin sensitizing effects may prove to be beneﬁ  cial in 
the treatment of non-alcoholic fatty liver disease (reviewed in 
Caldwell et al (2006)). TZDs should be avoided in patients 
with CHF, severe edema or macular edema. TZDs are 
considered class C for pregnancy (GlaxoSmithKline 2007; 
Takeda Pharmaceuticals 2007). Any metformin containing 
drug should be stopped before radiologic procedures with 
iodinated IV contrast for risk of lactic acidosis. No data is 
available for combined use of metformin-TZD in pediatric 
patients.
Rosiglitazone is predominantly metabolized by CYP2C8, 
and to a lesser extent, CYP2C9. Gemﬁ  borzil increases rosi-
glitazone levels. Rifampin reduceds rosiglitazone levels. 
Furosimide increases metformin levels, as does Nifedipine. 
Cationic drugs (eg, amiloride, digoxin, morphine, trim-
ethoprim, and vancomycin and others) that are eliminated 
by renal tubular secretion theoretically have the potential 
for interaction with metformin by competing renal excretion 
(GlaxoSmithKline 2007). Pioglitazone is metabolized by 
CYP2C8 and to a lesser extent CYP3A4, thus drug inter-
actions include midazolam, nifedipine ER, ketoconazole, 
atorvastatin (Takeda Pharmaceuticals 2007). Full details 
of cautions, contraindications, drug interactions and phar-
macokinetics are available in the prescribing information 
from the manufactures (GlaxoSmithKline 2007; Takeda 
Pharmaceuticals 2007).
Availability
Rosiglitazone-metformin (Avandamet™) is available in the 
following doses of rosiglitazone/metformin, respectively; 
1 mg/500 mg, 2 mg/500 mg, 4 mg/500 mg, 2 mg/1000 mg, 
4 mg/1000 mg. Rosiglitazone-metformin can be titrated 
up to a maximal total daily dose of 8 mg/2000 mg 
(GlaxoSmithKline 2007). One published study of healthy 
volunteers received; metformin 500 mg, rosiglitazone 
2 mg, or each twice daily for four days. Coadministration 
of rosiglitazone and metformin had no effects on steady 
state pharmacokinetics of either drug (Di Cicco et al 2000). 
Pioglitazone-metformin (Actoplus Met™) is available in 
doses of pioglitazone/metformin, respectively of; 15 mg/500 mg 
or 15 mg/850 mg with recommended maximal daily dosing 
of 45 mg/2550 mg (Takeda Pharmaceuticals 2007).
Mechanisms of action
The glucose lowering effects of metformin are largely 
attributable to an increase in glucose uptake by muscle and 
decrease in hepatic glucose production (Perriello et al 1994; 
Bailey and Turner 1996; Large and Beylot 1999; Hundal 
et al 2000). TZDs primarily act to improve insulin sensitiv-
ity (reviewed in Yki-Jarvinen 2004). Detailed summaries of 
the mechanisms of action of both metformin and TZDs have 
been reviewed elsewhere and are beyond the scope of this 
review (Bailey and Turner 1996; Kirpichnikov et al 2002; 
Yki-Jarvinen 2004). This section focuses on potential cellular 
and molecular mechanisms by which the combined use of 
metformin and TZD may be beneﬁ  cial, and also mechanisms 
of possible side effects.
AMP-activated protein kinase (AMPK) is a heterotri-
meric complex which responds to the energy status of the cell 
in that an increase in the AMP:ATP ratio causes threonine 
phosphorylation, and thus activation of AMPK (Hawley et al 
1996). In response to AMPK activation the cell decreases 
ATP-consuming and increases ATP-producing pathways, 
thus a potential metabolic sensor for the cell (Hardie et al 
1998). Both Metformin and TZDs activate AMPK through 
distinct pathways, thus AMPK may be a mediator of the 
protective effects of metformin and TZDs on insulin action 
(Fryer et al 2002).
The efﬁ  cacy of combination of TZD and metformin may 
be in part due to prevention of fatty-acid induced insulin Vascular Health and Risk Management 2007:3(4) 508
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resistance, or lipotoxicity (the concept of lipotoxicity is 
reviewed in Unger (2005)). Ye and colleagues demonstrated 
by hyperinsulinemic clamp studies in rats that both metformin 
and rosiglitazone improved insulin sensitivity, by improv-
ing insulin-mediated suppression of hepatic glucose output 
(Ye et al 2004). Rosiglitazone additionally enhanced free fatty 
acid (FFA) clearance, measured by 3H-R-bromopalmitate 
tracer technique (Ye et al 2004). Rosiglitazone increased FFA 
uptake by adipose and reduced uptake by the liver and muscle, 
as well as decreased liver long-chain CoA accumulation, a 
potential mediator of fatty-acid induced insulin resistance 
(Lee et al 1994; Ye et al 2004). Additionally this group has 
demonstrated that pioglitazone protects from FFA-induced 
insulin resistance in the liver (Ye et al 2002).
In addition to fatty acids, many inﬂ  ammatory mediators, 
when elevated, can cause insulin resistance in animal models 
and may contribute to the pathogenesis of DM2. These in-
clude CRP, an important protein in leptin action (Chen et al 
2006), and TNFα (reviewed in Moller 2000). In one double 
blind RCT of patients with metabolic syndrome, rosiglitazone 
8 mg qd for 12 wks, increased adiponectin, lowered resistin, 
CRP and TNFα (Samaha et al 2006). Adiponectin levels are 
inversely correlated with cardiovascular risk, thus an increase 
would be predicted to beneﬁ  t cardiovascular health (Pischon 
et al 2004). Lowering levels of resistin, CRP and TNFα 
should contribute to improved insulin resistance. In the study 
by Samaha, however, despite beneﬁ  cial changes in inﬂ  am-
matory mediators of insulin resistance, there was very little 
improvement in other clinical parameters known to contribute 
to cardiovascular risk, with an increase in total cholesterol, and 
no signiﬁ  cant changes in HDL or LDL (Samaha et al 2006).
In addition to the effects on FFA ﬂ  ux and glucose, 
TZD treatment may have beneﬁ  cial effects on vascular 
health directly. PPAR gamma is expressed in endothelial 
cells, and may have important role in vascular restenosis 
(reviewed in (Bruemmer et al 2005). In cultured endothelial 
cells ligand activation of PPAR gamma has been shown to 
inhibit thrombin-induced endothelin-1 production (Delerive 
et al 1999) and plasminogen activator inhibitor type 1 
expression (Kato et al 1999). In people, progression of 
carotid intima-media thickness, a marker of atheroscle-
rotic disease, is improved with pioglitazone (Mazzone 
et al 2006). In one double blind RCT, diabetic patients were 
treated with metformin or rosiglitazone. In the rosiglitazone 
group, intra-arterial acethylcholine-mediated vasoidailation 
(an indicator of arterial endothelial function) was improved 
by 40% and correlated with a decrease in FFA and TNFα 
(Natali et al 2004).
In summary, the combined use of metformin and a TZD 
have signiﬁ  cant improvements in glycemic control. The main 
efﬁ  cacy of combined therapy seems to be the effect of met-
formin to decrease endogenous glucose production and that 
of TZDs to improve insulin sensitivity, together targeting two 
key pathophysiologic defects in DM2. Single pill combina-
tions of both rosiglitazone-metformin (Avandamet™), and 
pioglitazone-metformin (Actoplus Met™) are available in 
Europe and the US. It is important to emphasize that potential 
cardiovascular beneﬁ  ts from the combined use of metformin 
and a TZD are not established in clinical trials. While there is 
data on the cardiovascular beneﬁ  t of both drugs individually, 
UKPDS for metformin and PROactive for pioglitazone 
(UKPDS 1998; Dormandy et al 2005), little distal outcome data 
for the combined use of these agents in terms of morbidity or 
mortality is currently available. The RECORD (rosiglitazone 
evaluated for cardiac outcomes and regulation of glycemia 
in diabetes) study is underway, one arm of which will test 
rosiglitazone added to metformin for cardiovascular outcomes 
and progression of diabetes (Ovalle and Bell 2004).
Search criteria
In addition to the authors’ personal knowledge of the 
literature in this ﬁ  eld, databases reviewed include medline/
pubmed 1966 to May Week 5 2006, Cochrane Central Reg-
ister of Controlled Trials, Cochrane Database of Systematic 
Reviews, EBM Reviews-Database of Abstracts of Reviews 
of Effects, ACP Journal Club 1991 to May/June 2006. Search 
terms included Rosiglitazone/troglitazone/pioglitazone AND 
Metformin, thiazolidinedione, vascular, cardiovascular, 
endothelial, diabetes, insulin resistance.
Abbreviations
Thiazolidinedione (TZD), type two diabetes mellitus (DM2), 
impaired glucose tolerance (IGT), total cholesterol (TC), 
triglycerides (TG), low-density lipoproteins (LDL), high-
density lipoproteins (HDL), free fatty acids (FFA), fasting 
plasma glucose (FPG), hemoglobin A1C (A1C), randomized 
control trial (RCT), Cardiovascular disease (CVD), conges-
tive heart failure (CHF).
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